NCT05171049 2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3 Terminated
Clinical Trials
10 trialsNCT07005024 2026-02-05
DOAC
University of Vermont
Phase 3 Recruiting
NCT07160686 2025-09-08
THROMBO-STOP
University of Birmingham
Phase 3 Not yet recruiting
NCT02066454 2025-08-13
MYELAXAT
University Hospital, Grenoble
Phase 3 Completed
NCT03045406 2025-06-24
CARAVAGGIO
Fadoi Foundation, Italy
Phase 3 Completed
NCT03080883 2025-05-18
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Academic and Community Cancer Research United
Phase 3 Completed
NCT03692065 2025-02-06
API-CAT
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT02369653 2022-03-08
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
Bristol-Myers Squibb
Phase 3 Completed
NCT02585713 2020-08-04
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
Phase 3 Completed
NCT04462003 2020-07-08
DVT
Beni-Suef University
Phase 3 Unknown